Pearl Diagnostics (MycoMed Technologies) creates products to establish early diagnosis of invasive fungal infections, which are common causes of death in people with immune suppression and poor lung function. The company has licensed novel technology from Johns Hopkins University that enables detection of microbial vesicles excreted from the body in urine, forming the basis of several early diagnostics for lung infections. Ultimately, Pearl Diagnostics will allow for early treatment of these infections, resulting in avoiding preventable deaths.
Location: United States, Maryland, Baltimore
Total raised: $3.5M
Investors 3
| Date | Name | Website |
| - | TEDCO | tedcomd.co... |
| 08.07.2022 | Creative D... | creativede... |
| - | Johns Hopk... | ventures.j... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.07.2022 | Seed | $3.5M | - |